Tranexamic Acid (TXA) Prophylaxis in Patients with Hematologic Malignancies
There wasn’t enough proof to support the preventive use of tranexamic acid (TXA) in...
Read More
Hematology/Oncology
Prostate Cancer Patients with Localized Prostate Cancer – Transcriptomic Indicators of Potential Therapeutic Response
Androgen axis modulators, PARP inhibitors, and PSMA theranostics have all been demonstrated to...
Read More
Metastatic Castrate-sensitive Prostate Cancer and Dynamic Changes in Pain Reported by Patients
Patients with metastatic castrate-sensitive prostate cancer (mCSPC) must deal with pain as a...
Read More
Patients with mHSPC do Not Seem to Be Able to Correlate CRFS With OS
Researchers had previously demonstrated the potential validity of radiographic progression-free...
Read More
Mutations of SPOP (mtSPOP) as Treatment Selection Biomarkers
For patients with mCSPC, the current standard of treatment is to intensify androgen deprivation...
Read More
Castration-resistant Prostate Cancer and Prostate-specific Antigen Decline
When added to the protocol-allowed standard of care (SoC) in patients with progressive,...
Read More
In CHAARTED and STAMPEDE, DOC was Combined with ADT for 6 Cycles
ADT + DOC was adopted as the norm for care in MHSPC. Clinical studies CHAARTED and STAMPEDE...
Read More
Detection Of HRR Gene Mutations (HRRm) In Tumour Tissue (TT) And Circulating Tumour DNA
Patients were enrolled in PROpel regardless of the presence of HRR gene mutations (HRRm). The...
Read More
1369P Biochemical Outcomes from ARTO Trial: AA and SBRT in CRPC Patients
Abiraterone Acetate (AA) and stereotactic body radiotherapy (SBRT) were evaluated in the...
Read More
Sexual Dysfunction Common Among Young Women With Cancer
FRIDAY, Sept. 30, 2022 (HealthDay News) — More than 60 percent of young women diagnosed with...
Read More
Novel Inherited Variants May Raise Risk for Hodgkin Lymphoma
FRIDAY, Sept. 30, 2022 (HealthDay News) — Novel coding and noncoding gene variants have been...
Read More
Patient’s ABO Blood Group and Clinical Spectrum of Chronic Myeloid Leukemia
Multiple analyses and investigations into the molecular mechanisms behind ABO blood type antigen...
Read More
Treatment Of (mCRPC) with Talazoparib Monotherapy: 1368P TALAPRO-1
Men with progressing mCRPC, detectable soft tissue disease, and tumor DDRm engaged directly or...
Read More
Prostate cancer: JNJ-70218902 (JNJ-902), A TMEFF2 x CD3 Bispecific Antibody
JNJ-902 is a bispecific antibody that binds to CD3 on T cells and TMEFF2-expressing tumor cells....
Read More
Prostate Cancer Diagnosis and Treatment in Relation To COVID-19
The COVID-19 pandemic has a worldwide influence on cancer detection and treatment. For example,...
Read More
Impact of PSMA Positive Tumor Cells: Men with Metastatic Castrate-resistant Prostate Cancer
Results in males with mCRPC have significantly improved thanks to PSMA-targeted radioligand...
Read More
CYPIDES Study Results of the ODM-208 in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients
The first and rate-limiting enzyme in steroid production, CYP11A1, is specifically inhibited by...
Read More
Analyzing Cabazitaxel Every Two Weeks or Every Three Weeks
In mCRPC patients (pts) previously treated with docetaxel (DOC) and the alternative...
Read More
Comparing Pembrolizumab + Olaparib to Abiraterone (abi) Or Enzalutamide (enza)
Effective therapy was still needed for patients with severely pretreated mCRPC. Therefore,...
Read More
The PEACE-1 Phase III Trial Shows That 8-Month PSA Predicts Outcomes in Metastatic Castration-Sensitive Prostate Cancer Patients
In the PEACE-1 phase 3 study, men with de novo metastatic castration-sensitive prostate cancer...
Read More